AnaptysBio plans to release further data on rosnilimab and other pipeline assets in 2025, including studies for ulcerative colitis. These developments highlight AnaptysBio's ongoing efforts in ...

Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of ...

They have a few legacy molecules that they are not actively pursuing in their pipeline. These are ANB032 and Imsidolimab. They keep running these through trials and then dropping them from the ...

Leading AnaptysBio’s pipeline is rosnilimab, which is currently being evaluated for several conditions, including rheumatoid arthritis (RA) and ulcerative colitis (UC). The company recently delivered ...

AltaGas Ltd (ALA.T) is expected to report $0.70 for 4Q. AnaptysBio Inc (ANAB) is expected to report $-1.62 for 4Q. Astria Therapeutics Inc (ATXS) is expected to report $-0.45 for 4Q. Biglari ...

Leading AnaptysBio’s pipeline is rosnilimab, which is currently being evaluated for several conditions, including rheumatoid arthritis (RA) and ulcerative colitis (UC). The company recently ...

The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with ... no longer appears in its pipeline listing.

Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the ...

Anaptys has cash, cash equivalents and investments greater than $420M as of December 31, 2024, and anticipates receipt of a $75M commercial ...

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.